Navigation Links
BioAtom Inc. To Present at BIOCOM Investor Conference 2008

SAN DIEGO, Oct. 27 /PRNewswire/ -- BioAtom Inc. (private) announced today that it will present at the 3rd annual BIOCOM Investor Conference on Tuesday, October 28, 2008 at 2:30 PM PDT (5:30 PM EDT) at the Hyatt Regency La Jolla in San Diego, California.

Myron Karasik, M.B.A., C.M.C., Director of Finance, will present an overview of Medical Division of BioAtom Inc. of Costa Mesa, CA, dedicated to development and commercialization of Neutron Cancer Diagnostics. Its ONCOSENSOR(TM), a nanotechnology probe, will undergo in vivo evaluation at Center for Functional Onco Imaging, UC Irvine, in collaboration with Radiation Oncology Group, Long Beach Memorial Hospital.

From Bomb Detector to Cancer Diagnostic Probe. Malignant tumors are chemically different from normal tissue. ONCOSENZOR(TM) can non-invasively detect in vitro chemical differences as small as 1 atom/molecule. Its core technology was developed under US Army contracts for non-intrusive detectors of bioagents and explosives in a previous company (no longer in existence), by co-founders of BioAtom, at a cost to shareholders of over $40 million.

Our mission is to provide an early warning, walk-in, painless (non-invasive) and "instant" (online) cancer diagnosis aid that is a quantum leap ahead of competing firms. Operating in tandem with any one of the imaging probes, we hope to ultimately achieve needle-less biopsy. The method has the potential for forewarning of stroke, Alzheimer, and cardiovascular diseases.

Marketing of ONCOSENZOR(TM) to animal clinics, a $13 Billion/year market, does not require FDA approval.

Anna Radovic, Ph.D., 36, President and Chief Scientific Officer, an international cancer researcher and co-patentee, was first to irradiate DNA by neutrons. Christian Druey, B.E.E., 38, has been instrumental in commercialization of medical imaging and explosive detection devices. Bogdan Maglich, Ph.D., CTO and Chairman, the inventor of the core technology, has been elected one of "50 Champions of Innovation" worldwide.

TV interviews: (1) (2006); (2), (2007) season 2 episode 7. Company has no general non-NDA website as a matter of proprietary policy.

Safe Harbor Statement

This press release contains certain forward-looking statements and projections which include, but are not limited to, references to BioAtom's technology, strategy, and ability to commercialize a novel diagnostic aid. Uncertainties and other factors may cause the actual results to materially differ from those predicted. BioAtom does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

SOURCE BioAtom Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oncothyreon to present at BIO Investor Forum 2008
2. China Yingxia to Present at Rodman & Renshaw Annual Global Investment Conference
3. Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
6. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
7. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
8. New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence
9. Celator(R) Pharmaceuticals To Present at 2008 BIO Investor Forum
10. Rosetta Genomics to Present at the Upcoming EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer"
11. Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium
Post Your Comments:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... operations for Amgen, will join the faculty of the University of North ... adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on ...
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology:
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):